anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Economists originally developed methods to assess financial catastrophe using total or aggregate out-of-pocket health spending. Aggregate out-of-pocket health spending is financially catastrophic when it exceeds a fixed proportion (i.e., threshold) of a household's total income or expenditure in a given period. However, these methods are now applied to assess financial catastrophe in disease- or service-specific rather than aggregate out-of-pocket health spending without using disease- or service-specific thresholds. This paper argues that not using disease- or service-specific thresholds for such assessments is misleading and underestimates the burden of financial catastrophe, especially among households from poorer backgrounds. It then proposed disease- or service-specific catastrophic payment thresholds, applied them to Nigeria and found that financial catastrophe was underestimated for the five service groups considered. The paper stresses the importance of using disease- or service-specific thresholds and avoiding unadjusted thresholds, which may leave poorer households behind as financially protected.
PCT No. PCT/HU91/00039 Sec. 371 Date Jun. 5, 1992 Sec. 102(e) Date Jun. 5, 1992 PCT Filed Aug. 23, 1991 PCT Pub. No. WO92/03126 PCT Pub. Date Mar. 5, 1992.The invention relates to a process for the preparation of a tablet or dragée composition containing a moisture-, heat- and light-sensitive compounds having monoclinic crystalline structure as active ingredients, which comprises homogenizing the active ingredient with 0.2 to 1.5 parts by weight of an anhydrous alkaline earth metal salt and 0.5 to 2.5 parts by weight of microcrystalline cellulose calculated for the active ingredient and optionally with one or more pharmaceutically acceptable carrier(s) and/or additive(s) and compressing the homogeneous mixture obtained to tablets in a manner known per se and, if desired, coating the tablet thus obtained in a manner known per se.
For this single case research design with alternating treatments without baseline, 5 control volunteers and 5 participants with severe speech and physical impairment who have AUC scores between 70-80% will complete copy spelling tasks with BCI-FIT active querying technique on and with BCI-FIT active querying technique off. Outcome measures are typing accuracy, typing speed and user experience.
PURPOSE: A composition for treatment and prevention of osteoarthritis containing Fructus schizandrae extract having an action of inhibiting hyaluronidase is provided. It inhibits hyaluronic acid decomposition by hyaluronidase in a joint generally produced in osteoarthritis patients and the inhibition of an extracellular matrix of chondrocyte cells and therefore can be used as a drug and health food for prevention and treatment of arthritis. CONSTITUTION: The composition for treatment and prevention of osteoarthritis contains Fructus schizandrae extract as an effective component. The Fructus schizandrae extract is extracted by the steps of: extracting with methanol; pouring distilled water into the methanol extract and extracting with hexane; reextracting the extraction residue with chloroform; and extracting the extraction residue with ethyl acetate. The daily dose of the composition is 1 to 100mg/kg. For an example, 100mg Fructus schizandrae extract is mixed with 100mg corn starch, 100mg lactose and 2mg magnesium stearate to give a tablet.
Using VR training. 40 minutes per session, one session per week, and a total 8 weeks.
Transition metal ions enhance the ability of the body to increase vascularization, particularly for revascularizing damaged tissues, apparently because they enhance expression of the vegF gene, so as to increase VEGF levels. According, hypoxic tissue damage can be treated or prophylactically reduced by administering a composition comprising a transition metal ion capable of stimulating vascularization. Treatment can be accomplished using compositions of matter which include a transition metal ion in a sterile, biologically compatible carrier, packaged as a unit dosage effective to increase vascularization in hypoxic tissue. For systemic administration, the transition metal ion is formulated at a concentration that is non-toxic and ineffective to increase vascularization in non-hypoxic tissue. For local administration, the transition metal ions are formulated in a slow-releasing carrier to release the transition metal ions continually over a prolonged period in an amount effective to increase vascularization locally. For example, for topical application, the composition may be a salve, a gel, or a patch. For internal slow release or for topical application, the composition may be formulated in a slow release matrix.
Provided is an eating/swallowing function evaluation apparatus 1 for evaluating the eating/swallowing function of a subject. The eating/swallowing function evaluation apparatus is provided with an eating behavior information acquiring unit 103, a right/wrong information acquiring unit 108, an eating behavior evaluating information output unit 105, and a semantic memory evaluating information output unit 110. The eating behavior information acquiring unit acquires eating behavior information representing the eating behavior of a subject. The right/wrong information acquiring unit acquires right/wrong information representing a right or wrong answer of the subject to a semantic memory problem. The eating behavior evaluating information output unit, on the basis of the acquired eating behavior information, outputs eating behavior evaluating information representing the degree to which the eating behavior of the subject is normal. The semantic memory evaluating information output unit, on the basis of the acquired right/wrong information, outputs semantic memory evaluating information representing the degree to which the semantic memory function of the subject is normal.
Women scheduled for an elective cesarean section at term will be recruited to participate in this study. The investigators plan to recruit 100 women. Baseline demographic information will be obtained at the pre-op visit. Eligible subjects will be randomized to received a silver containing dressing (Acticoat PostOp) or the standard dressing (OpSite PostOp). A randomization table will be computer generated in blocks of 20. A sealed opaque envelope containing the assigned dressing will accompany the patient to the operating room. Standard antibiotic prophylaxis will be provided prior to skin incision. A subcuticular suture will be used for skin closure. At the time of skin closure, the envelope will be opened and the assigned dressing will be applied. The dressing will only be changed if it is saturated. The dressing will be removed at the time of discharge from hospital. A questionnaire regarding wound complications will be completed at the time of discharge from hospital, at 2 weeks post-op and 6 weeks post-op.
The invention belongs to the technical field of biology, and particularly relates to an amino acid fragment Z01 with osteogenic activity, and screening and application thereof. The invention self-establishes a specific cell screening platform aiming at Osx: CL-Osx-EGFP cell line. The cell screening platform fuses Osx and EGFP, the EGFP is used as a tracking marker, the expression change of Osx can be directly reflected, and a compound capable of activating Osx is screened out. Z01 can effectively activate Osx, and the amino acid sequence of the Z01 is shown as SEQ ID NO. 1. And carrying out pharmacokinetic analysis and toxicological detection on the Z01, and finally verifying the osteogenic activity of the Z01 in an osteoporosis animal model of an ovariectomized rat. Finally, the Z01 has osteogenic activity, can improve the microstructure of bones and increase the bone density, and has wide application range.
Soft tissue sarcomas (STS) originating from connective tissue rarely affect the lymph nodes. However, involvement of lymph nodes in STS is an important aspect of prognosis and treatment. Currently, there is no consensus on the diagnosis and management of lymph node metastases in STS. The key risk factor for nodal involvement is the histological subtype of sarcoma. Radiological and pathological evaluation seems to be the most effective method of assessing lymph nodes in these neoplasms. Thus, sentinel lymph node biopsy (SLNB), which has been shown to be valuable in the management of melanoma or breast cancer, may also be a beneficial diagnostic option in some high-risk STS subtypes. This review summarizes data on the risk factors and clinical characteristics of lymph node involvement in STS. Possible management and therapeutic options are also discussed.
Participants received elagolix 250 mg tablets once a day for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 250 mg for an additional 12 weeks.
This is a multi-centre, multi-country, double-blind, randomised, placebo-controlled Phase 2b study. The study will have a single-blind run-in period and will be adaptive with respect to the number of subjects recruited into each dose group. Four doses of BAY3427080 (40 mg once a day, 80 mg once a day, 120 mg once a day and 160 mg once a day) will be investigated and compared to placebo, in five parallel groups. Subjects will participate in the study for a total of approximately 19 weeks, comprising a screening period of 1 week, a 14 week treatment period, and then a final follow up visit 4 weeks after the end of the treatment period. There will be a total of 8 visits whilst participating in the study. Subjects will record their hot flashes in an electronic diary during the screening period to establish eligibility and throughout the study after randomisation.
The invention relates to the use of substances, which reversibly bind oxygen for transporting, transferring and for storing oxygen in order to provide oxygen during the growth of organs, organ-like structures, tissue cultures, cultures of human or animal cells or cultures of microorganisms. To this end, a number of possible properties of these substances can be used. The property of binding oxygen at a high partial pressure and releasing it once again into the surroundings at a low partial pressure whereby enabling a transport of oxygen is utilized. In addition, the ability to store oxygen and release it once again only in the event of very low partial pressures is utilized. The ability of some of these substances to transfer oxygen well in a variable manner is also utilized. Adding substances, which reversibly bind oxygen, to organ cultures, organoid cultures, tissue cultures, cell cultures or microorganism cultures makes it possible to achieve a sufficient provision of oxygen also in the areas in which, without these substances and under otherwise identical conditions, it would not be possible to provide oxygen for the survival or good functioning of cells or of microorganisms that require oxygen.
PURPOSE: A polynucleotide for drug metabolism prediction including single nucleotide polymorphism of a nr1i2 gene, a kit and a drug metabolism prediction method using thereof are provided to increase prediction probability and predict metabolic activation of bupropion according to process of rifampin by simple confirmation of genotype. CONSTITUTION: A marker for predicting drug metabolism includes polynucleotide or complement thereof consisting of 8-200 continuous DNA sequences which respectively include 705th,34403rd, and 34823rd DNAs of polynucleotide which is represented by sequence number 1[SEQ ID NO:1]. The drug is bupropion. The drug metabolism is metabolism of the bupropion according to administration of rifampin. In the metabolism of bupropion, the bupropion is converted into hydroxybupropion. A kit for drug metabolism prediction includes a marker for the drug metabolism prediction. The drug metabolism prediction method comprises the following steps: obtaining nucleic acid sample material which includes NR1I2 gene; amplifying the polynucleotide which respectively includes 705th, 34403rd, and 34823rd DNAs of polynucleotide which is represented by sequence number 1; and determining genotype of 705th, 34403rd, and 34823rd DNAs of the polynucleotide which is represented by sequence number among the amplified polynucleotides.
Non-pharmacological treatment methods, including lifestyle changes, are primarily recommended for the treatment of constipation. In cases where success is not achieved with this method, pharmacological agents, biofeedback and surgical treatment methods can be applied depending on the severity of constipation. Lifestyle changes include increasing fiber and fluid intake and regular physical activity Osteopathic manual therapy (OMT) is the examination and treatment of the function of the neuromusculoskeletal system anatomy using non-invasive, generally safe manual techniques to improve functional body mechanics such as joint range of motion, muscle tone, circulation, body fluid pressures and exchanges, and nerve impulses. OMT is used for autonomic system regulation, balancing pelvic muscle tone, increasing gastrointestinal motility, preventing myofascial limitations and increasing the pump effect of the diaphragm (5,6). The positive effects of OMT on the microbiome are available in the literature.

Alternative treatments are needed because the costs of combating constipation are high. Non-invasive interventions are especially gaining importance.
Bisphenol A (BPA) is a xenoestrogen which has been shown to cause abnormalities in sexual development and may lead to reproductive damage in animals. In epidemiological studies BPA has been associated with various health effects. The majority of dental plastic filling materials contain polymers synthesized from BPA. Whether BPA is released in vivo from polymer-based fillings and - if so, in what doses - is not sufficiently examined. Patients scheduled for regular dental examination at the public dental clinic, Bergen Downtown District, who needs therapy with dental polymer-based filling materials and is suitable for study (inclusion / exclusion criteria) will be informed about the project. If the patient wants to participate in the study, he/she will be given written information about the study and a consent form. It is emphasized that participation in the study is voluntary and the patient will have the opportunity to read the information at home, before the next appointment at the clinic. The clinical treatment of the carious lesion(s) will be performed according to standardized procedures and materials used at the clinic. After curing, the filling will be polished according to the standard procedures. The curing lamp will be controlled and documented weekly during the project period. All treatment sessions will be scheduled in the morning before 9 am. Questions regarding food intake and dental hygiene habits will be included in questionnaires answered during the study. Samples of saliva and urine will be collected immediately before filling placement and 1 hour, 24 hours and 1 week after treatment. A saliva sample will also be collected immediately after treatment. No food or drink intake is allowed after midnight before sample collection. Only tapped water is permitted. The sampling procedure will be controlled in advance, so that the risk of contamination of samples is minimized. After collection samples will be refrigerated and stored frozen at -80 °C until analysis. Bisphenol A in saliva and urine will be determined by liquid chromatography and mass spectrometry (LC-MS). The detection limit of the method is estimated at 0.1 ng BPA/ml. The study is approved by the Regional Committee for Medical and Health Research (reference number 2014/1529). Patients who participate in the project will have to collect saliva samples five times and urine samples four times, which involves extra visits to the clinic. The biomedical outcomes (concentration of bisphenol A in saliva and urine) will be assessed in a pre-defined group of individuals. The participants may be enrolled in the study if they fulfil the criteria (including need of a dental filling). The participants do not receive the intervention (placement of a dental filling) because they are enrolled in the study. Subjects in the study will receive the therapeutic intervention, but the investigator does not assign the intervention to the subjects of the study. Thus, the study may be described as an observational study.
The digital app will include 10 education modules addressing the major CVD risk factors to be delivered on-demand through an innovative, interactive video series. The digital app will also support the multi-media education modules, interactive surveys/quizzes, self-monitoring (diet, physical activity), and social networking (discussion board) functionality.
Active magnetic field exposure will be performed by use of a EMF resonator. Stimulator will be applied continuously for 1 hour.
PURPOSE:To provide a cosmetic exhibiting excellent skin moisturizing effect and beautifying effect, by compounding a cosmetic base with a juice obtained by treating a fruit of a plant of cucurbitaceae family with pectinase. CONSTITUTION:The skin and seed are removed from a fresh fruit of a plant of cucurbitaceae family, and the obtained pulp is ground and squeezed. The juice is added with a pectinase to decompose the pectin component, and filtered and sterilized after the deactivation of the enzyme. The juice obtained by the process and composed mainly of saccharides is added to the base of cosmetics such as skin cosmetics, hair cosmetics, oral cosmetics, soap, etc. in an amount of 5- 20wt%. The obtained cosmetic is effective to improve the color and luster of the skin, prevent wrinkles and beautify the skin.
Compositions may be used for a variety of therapeutic applications, including treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, such as aging or stress, diabetes, obesity, and neurodegenerative diseases. The compositions can be administered to an older adult or an elderly individual. It can also be administered to a patient in ICU. The compositions contain a combination of curcumin and an omega-3 fatty acid. The compositions can be food products, nutritional supplements or nutraceutical. The compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.
Software-based intervention simulating daily life cognitive challenges. Delivered 1 hour per day, 5 days per week for 4 weeks. Includes 8 check-in phone calls with an experimenter. Includes escalating challenge levels.
Symptoms associated with the discontinuation or dose reduction of mirtazapine tablets have been reported. Patients should be monitored for these and other symptoms when discontinuing treatment or during dosage reduction. A gradual reduction in the dose over several weeks, rather than abrupt cessation, is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, dose titration should be managed on the basis of the patient’s clinical response (see PRECAUTIONS and ADVERSE REACTIONS). 

  


Information for Patients

Patients should be advised that taking mirtazapine tablets can cause mild pupillary dilation, which in susceptible individuals, can lead to an episode of angle-closure glaucoma. Pre-existing glaucoma is almost always open-angle glaucoma because angle-closure glaucoma, when diagnosed, can be treated definitively with iridectomy. Open-angle glaucoma is not a risk factor for angle-closure glaucoma. Patients may wish to be examined to determine whether they are susceptible to angle-closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.
Anti-CD40 antibodies have not been reported to induce hemostatic events in patients, however elevations in pancreatic enzymes in B cell lymphoma patients receiving the anti-CD40 Ab Chir12.12 and the possible risk of pancreatitis precludes the use of this Fc-competent anti-CD40 antibody in chronic autoimmune disease and transplantation for safety reasons. We therefore generated Fc-silent IgG1 anti-CD40 antibodies (mAb1, mAb2 and mAb3) unable to mediate antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) both in vitro and in vivo. mAb1 was able to prolong non-human primate renal allograft survival in combination with sub-therapeutic doses of cyclosporine. In addition, mAb1 was able to completely suppress primary and secondary antibody responses to immunization with a T cell-dependent antigen. Crucially, there was no evidence of hemostatic events or abnormal pancreatic histology in either the transplant or immunization study. Collectively these results suggest mAb1 would be a safe and efficacious therapeutic, and could be used to treat patients suffering from B lymphocyte and antigen presenting cell driven autoimmune disease or undergoing allograft transplant where CD4O-CD154 interactions are involved in contributing to pathology.
PURPOSE: To obtain an aromatic agent, capable of emitting an aroma into the interior of a room for a long period by moderate heating and excellent in sustained release properties. CONSTITUTION: Thin aromatic agent is obtained by adsorbing or mixing a perfume or a cyclodextrin clathrate compound of the perfume with a powder of amorphous calcium phosphate(ACP) and forming the resultant material into the shape of a tablet, a plate, etc. The perfume in a dispersed state thereof mixed with a surfactant and water acts as a medium for dispersing and adsorbing the perfume on the ACP. The surfactant is used in order to uniformly and stably disperse the perfume in water. A mixture of the perfume with the surfactant, water, etc., in an amount of 10-150 pts.wt. based on 100 pts.wt. ACP is used and the surfactant in an amount of 50-200 pts.wt. based on 100 pts.wt. perfume is blended. Water in an amount of 10-1000 pts.wt. based on 1 pt.wt. perfume is blended therewith.  When an antimicrobial perfume (e.g. hinokitiol) is used as the perfume, antimicrobial activities are imparted in addition to the aroma.
This study combined qualitative and quantitative approaches to evaluate outcomes of isolated nonsyndromic unilateral lambdoid synostosis at the Children's Hospital of Philadelphia. Volumetric, linear, and angular analyses were performed on long-term postoperative and normal control scans. Preoperative and postoperative clinical photographs were evaluated for the presence of dysmorphic frontofacial features. Among 26 included patients, median age of surgery was 10 months and mean postoperative follow-up was 5.9 ± 5.7 years. Two (7.7%) patients underwent secondary cranial vault procedures. At most recent follow-up, 2 (7.7%) subjects reported intermittent headaches. Twenty (90.9%) of 22 patients were assigned Whitaker grade I. Among 9 subjects with long-term imaging at age 11.5 ± 5.3, posterior vault asymmetry, posterior fossa deflection angle, cranial base angle, and ear position asymmetry all remained greater than in the control group. Of subjects included in the frontofacial feature analysis (n = 10), 50% had resolution of all dysmorphic frontofacial features present preoperatively. Overall, most subjects who underwent PVR did not require revisional surgery and had good outcomes both aesthetically and functionally. Despite residual abnormalities in the cranial base and posterior vault, most had resolution of parietal bossing and facial scoliosis. Ear position asymmetry was the most common dysmorphic feature at long-term follow-up.